Coronavirus | Dr. Reddy’s initiates Emergency Use Authorisation process for Sputnik V


Sputnik V is one of only three vaccines in the world with an efficacy of 91.6% and has most authorisations granted with 26 countries globally, says company.

Dr. Reddy’s Laboratories Ltd. on Friday announced that it had initiated the process with the Drugs Controller General of India (DCGI) for Emergency Use Authorisation (EUA) of human adenoviral vector-based platform vaccine candidate Sputnik V.

“As part of the review process, Dr. Reddy’s will present the safety profile of the phase-two study, and interim data of the phase-three study, which is expected to complete by 21st February 2021,” noted a release issued by the company.

Coronavirus | Sputnik V COVID-19 vaccine shows interim efficacy of 91%

G V Prasad, Co-chairman and Managing Director of Dr. Reddy’s Laboratories, said, “The efficacy of Sputnik V was reported to be 91.6 % by The Lancet, which is an impressive development in the fight against COVID-19. The initiation of the EUA process will be a critical step forward for us in ensuring speedy access to the Sputnik V vaccine in India.”

Sputnik V, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology, was registered by the Ministry of Health of Russia on August 11, 2020 and became the world’s first registered vaccine against COVID-19 based on the human adenoviral vector platform.

Read: Sputnik V vaccine launch likely in March

“More than 250 clinical studies over two decades have proven the safety, efficacy, and lack of negative long-term effects of adenoviral vaccines. Sputnik V is one of only three vaccines in the world with an efficacy of 91.6% and has most authorisations granted with 26 countries globally. The vaccine has already been administered to more than 2 million people worldwide,” the release stated.

It further said that in September 2020, Dr. Reddy’s partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and for its distribution rights in India.

“The vaccine is currently undergoing the phase three clinical trial in India. Sputnik V has demonstrated an efficacy rate of 91.6% in the interim analysis of the phase 3 clinical trial, which included data on 19,866 volunteers in Russia, who received both the first and second doses of the vaccine. Sputnik V maintained a consistent efficacy at 91.8% even among the group of 2,144 volunteers over 60 years old,” said the company.

You have reached your limit for free articles this month.

Subscription Benefits Include

Today’s Paper

Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.

Unlimited Access

Enjoy reading as many articles as you wish without any limitations.

Personalised recommendations

A select list of articles that match your interests and tastes.

Faster pages

Move smoothly between articles as our pages load instantly.

Dashboard

A one-stop-shop for seeing the latest updates, and managing your preferences.

Briefing

We brief you on the latest and most important developments, three times a day.

Support Quality Journalism.

*Our Digital Subscription plans do not currently include the e-paper, crossword and print.

A letter from the Editor


Dear subscriber,

Thank you!

Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.

The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.

We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.

Suresh Nambath



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *